OCCURRENCE OF CYTOMEGALOVIRUS RETINITIS AFTER HUMAN-IMMUNODEFICIENCY-VIRUS IMMUNOSUPPRESSION

Objective: To estimate the incidence and prevalence of cytomegalovirus retinitis (CMV-R) in late-stage human immunodeficiency virus type 1 d isease. Design: Cohort study. Setting: The Multicenter AIDS Cohort Stu dy, an ongoing 10-year study of human immunodeficiency virus type 1-in fected homosexual men with semiannual visits and CD4(+) cell testing. Study Participants: Three hundred sixty-seven human immunodeficiency v irus type 1-infected men from the Multicenter AIDS Cohort Study who we re receiving zidovudine and Pneumocystis carinii prophylaxis and who h ad CD4(+) cell counts fall below 0.10x10(9)/L (100/mu L). Main Outcome Measures: Kaplan-Meier-type estimates for various longitudinal quanti fications of incidence and prevalence of CMV-R were obtained. Results: Among these 367 individuals, cytomegalovirus disease developed in 103 , of whom 73 (71%) had ocular complications. At 4 years after the firs t CD4 cell count (<0.10x10(9)/L), the probability for these subjects t o have (1) remained living without CMV-R was 11%, (2) died without exp eriencing CMV-R was 66%, (3) experienced CMV-R and be living was 6%, a nd (4) experienced CMV-R and died was 18%. During these 4 years; there was a 25% chance for the development of CMV-R and, on average, 0.211 person-years of CMV-R morbidity. Among those subjects in whom CMV-R de veloped, about 19% did have CMV-R before a CD4(+) cell count of less t han 0.05x10(9)/L (<50/mu L) was observed, and 81% had CMV-R after the CD4(+) cell count reached this threshold. Conclusion: These estimates may be relevant to current clinical practice and help in allocating re sources and planning for treatment and prophylaxis against cytomegalov irus disease.